
New appointments for AstraZeneca’s Mene Pangalos
pharmafile | November 13, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
Dr Mene Pangalos, executive vice president of the IMED Biotech Unit at AstraZeneca UK, has accepted two prestigious appointments that the companies says “reflects AstraZeneca’s long standing commitment to strengthening UK science.”
With immediate effect, Pangalos will join the board of the Precision Medicine Catapult – the newly established Cambridge based centre designed to shape the future of precision medicine research in the UK.
In his role as a non-executive director Pangalos will help set the strategic direction of the Precision Medicine Catapult, providing a pharmaceutical industry perspective on how to ensure the UK can remain at the cutting edge of precision medicine science.
Alongside this appointment, Pangalis has been elected as an official fellow of Clare Hall College, at the University of Cambridge. As a fellow he will support the governing body, with a particular focus on more open research where scientists from industry and academia can work side by side.
Pangalos comments: “I’m delighted to receive these two appointments. Although they are a great personal honour, I believe they are testament to the quality of our science, our pioneering approach to personalised healthcare and our long standing commitment to strengthening the UK life science sector.”






